Clinical perspectives of hybrid proton-fluorine magnetic resonance imaging and spectroscopy

Investigative Radiology

Volumn 48, Issue 5, 2013, Pages 341-350

  Wolters, Martijn ^a,b   Mohades, Seyede G ^a,b,c   Hackeng, Tilman M ^b,d   Post, Mark J ^b,d   Kooi, Marianne E ^a,b   Backes, Walter H ^a,b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

dual targeted MRI; fluorine 19; magnetic resonance; molecular imaging; nanoparticle; perfluorocarbon

Indexed keywords

CONTRAST MEDIUM; FLUORINE; FLUOROURACIL; FLUOXETINE; FLUPHENAZINE; FLUVOXAMINE; GADOLINIUM; HALOPERIDOL; NANOPARTICLE; NORASTEMIZOLE; PAROXETINE; PERFLUOROOCTYL BROMIDE; SITAFLOXACIN;

ARTICLE; CELL LABELING; DEGENERATIVE DISEASE; EMULSION; FLUORINE NUCLEAR MAGNETIC RESONANCE; HEART INFARCTION; HUMAN; LUNG VENTILATION; MAGNETIC RESONANCE ANGIOGRAPHY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXYGEN TENSION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RADIATION DOSE; SCINTIGRAPHY; SIGNAL DETECTION; TUMOR LOCALIZATION; TUMOR VOLUME;

CONTRAST MEDIA; FLUORINE; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; PROTONS;

EID: 84876258604     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e318277528c     Document Type: Article

References (122)

1. Mulder WJ, Strijkers GJ, Vucic E, et al. Magnetic resonance molecular imaging contrast agents and their application in atherosclerosis. Top Magn Reson Imaging. 2007;18:409-417.
2. Thomas SR, Ackerman JL, Goebel JR, et al. Nuclear magnetic resonance imaging techniques as developed modestly within a university medical center environment: what can the small system contribute at this point? Magn Reson Imaging. 1982;1:11-22.
3. Clark LC Jr, Ackerman JL, Thomas SR, et al. Perfluorinated organic liquids and emulsions as biocompatible NMR imaging agents for 19F and dissolved oxygen. Adv Exp Med Biol. 1984;180:835-845.
4. Hinshaw WS, Bottomley PA, Holland GN. Radiographic thin-section image of the human wrist by nuclear magnetic resonance. Nature. 1977;270:722-723.
5. Noth U, Rodrigues LM, Robinson SP, et al. In vivo determination of tumor oxygenation during growth and in response to carbogen breathing using 15C5-loaded alginate capsules as fluorine-19 magnetic resonance imaging oxygen sensors. Int J Radiat Oncol Biol Phys. 2004;60:909-919.
6. Magat J, Jordan BF, Cron GO, et al. Noninvasive mapping of spontaneous fluctuations in tumor oxygenation using 19F MRI. Med Phys. 2010;37: 5434-5441.
7. Myerson J, He L, Lanza G, et al. Thrombin-inhibiting perfluorocarbon nano-particles provide a novel strategy for the treatment and magnetic resonance imaging of acute thrombosis. J Thromb Haemost. 2011;9:1292-1300.
8. Morawski AM, Winter PM, Yu X, et al. Quantitative ''magnetic resonance immunohistochemistry'' with ligand-targeted (19)F nanoparticles. Magn Reson Med. 2004;52:1255-1262. doi:10.1002/mrm.20287.
9. Srinivas M, Heerschap A, Ahrens ET, et al. 19F MRI for quantitative in vivo cell tracking. Trends Biotechnol. 2010;28:363-370.
10. McIntyre DJ, Howe FA, Ladroue C, et al. Can localised 19F magnetic resonance spectroscopy pharmacokinetics of 5FU in colorectal metastases predict clinical response? Cancer Chemother Pharmacol. 2011;68:29-36.
11. Schlemmer HP, Becker M, Bachert P, et al. Alterations of intratumoral pharmacokinetics of 5-fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy. Cancer Res. 1999;59:2363-2369.
12. Ruiz-Cabello J, Barnett BP, Bottomley PA, et al. Fluorine (19F) MRS and MRI in biomedicine. NMR Biomed. 2010;24:114-129.
13. Chen JJ, Lanza GM, Wickline SA. Quantitative magnetic resonance fluorine imaging: today and tomorrow. Wiley Interdiscip Rev Nanomed and Nano-biotechnol. 2010;2:431-440.
14. Diaz-Lopez R, Tsapis N, Fattal E. Liquid perfluorocarbons as contrast agents for ultrasonography and (19)F-MRI. Pharm Res. 2010;27:1-16.
15. Lanza GM, Winter PM, Neubauer AM, et al. 1H/19F magnetic resonance molecular imaging with perfluorocarbon nanoparticles. Curr Top Dev Biol. 2005;70:57-76.
16. Wolf W, Presant CA, Waluch V. 19F-MRS studies of fluorinated drugs in humans. Adv Drug Deliv Rev. 2000;41:55-74.
17. Stoll G, Basse-Lusebrink T, Weise G, et al. Visualization of inflammation using (19) F-magnetic resonance imaging and perfluorocarbons. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2012;4:438-447.
18. Temme S, Bonner F, Schrader J, et al. 19F magnetic resonance imaging of endogenous macrophages in inflammation. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2012;4:329-343.
19. Bachert P, Schröder L. Magnetic resonance spectroscopy. Part 1: basics [in German]. Radiologe. 2003;43:113-1128.
20. MacKenzie KJD, Smith ME. Pergamon material series. In: Multinuclear Solid-State Nuclear Magnetic Resonance of Inorganic Materials. Oxford, UK: Elsevier Science Ltd; 2004;6.
21. Dardzinski BJ, Sotak CH. Rapid tissue oxygen tension mapping using 19F inversion-recovery echo-planar imaging of perfluoro-15-crown-5-ether. Magn Reson Med. 1994;32:88-97.
22. Giraudeau C, Flament J, Marty B, et al. A new paradigm for high-sensitivity 19F magnetic resonance imaging of perfluorooctylbromide. Magn Reson Med. 2010;63:1119-1124.
23. Jerusalem THUo. Department of Organic Chemistry. The NMR Lab. 19 February 2008, 2008. Available at: http://chem.ch.huji.ac.il/nmr/index.html. Accessed October 5, 2008.
24. Bringmann G, Wolf K, Meininger M, et al. In vivo 19F NMR chemical-shift imaging of Ancistrocladus species. Protoplasma. 2001;218:134-143.
25. Srinivas M, Cruz LJ, Bonetto F, et al. Customizable, multi-functional fluor-ocarbon nanoparticles for quantitative in vivo imaging using 19F MRI and optical imaging. Biomaterials. 2010;31:7070-7077.
26. Chekmenev EY, Chow SK, Tofan D, et al. Fluorine-19 NMR chemical shift probes molecular binding to lipid membranes. J Phys Chem B. 2008;112: 6285-6287.
27. Wilson SR, Burns PN. Microbubble-enhanced US in body imaging: what role? Radiology. 2010;257:24-39.
28. Barnett BP, Ruiz-Cabello J, Hota P, et al. Fluorocapsules for improved function, immunoprotection, and visualization of cellular therapeutics with MR, US, and CT imaging. Radiology. 2010;258:182-191.
29. Cormode DP, Mulder WJ, Fayad ZA. Science to practice: versatile method to track transplanted encapsulated islet cells with multiple imaging modalities. Radiology. 2011;258:1-2.
30. Kornmann LM, Reesink KD, Reneman RS, et al. Critical appraisal of targeted ultrasound contrast agents for molecular imaging in large arteries. Ultrasound Med Biol. 2009;36:181-191.
31. Park BK, Kitteringham NR, O'Neill PM. Metabolism of fluorine-containing drugs. Annu Rev Pharmacol and Toxicol. 2001;41:443-470.
32. Muller K, Faeh C, Diederich F. Fluorine in pharmaceuticals: looking beyond intuition. Science. 2007;317:1881-1886.
33. Zhang H. Perfluoro-15-crown-5 ether-labeled dendritic cells. In: Molecular Imaging and Contrast Agent Database (MICAD) (Internet). Bethesda, MD: National Center for Biotechnology Information; 2004-2012. Available at: http://www.ncbi.nlm.nih.gov/books/NBK23192/. Accessed May 2012.
34. Schwitter J. Extending the frontiers of cardiac magnetic resonance. Circulation. 2008;118:109-112.
35. Nieuwoudt M, Engelbrecht GH, Sentle L, et al. Non-toxicity of IV injected perfluorocarbon oxygen carrier in an animal model of liver regeneration following surgical injury. Artif Cells Blood Substit Immobil Biotechnol. 2009; 37:117-124.
36. Krafft MP, Riess JG. Perfluorocarbons: life sciences and biomedical usesVdedicated to the memory of Professor Guy Ourisson, a true renaissance man. J Polym Sci, Part A:Polym Chem. 2007;45:1185-1198.
37. Riess JG. Perfluorocarbon-based oxygen delivery. Artif Cells Blood Substit Immobil and Biotechnol. 2006;34:567-580.
38. Riess JG. Fluorocarbon-based in vivo oxygen transport and delivery systems. Vox Sang. 1991;61:225-239.
39. Hess JR. Update on alternative oxygen carriers. Vox Sang. 2004;87:132-135.
40. Jahr JS, Walker V, Manoochehri K. Blood substitutes as pharmacotherapies in clinical practice. Curr Opin Anaesthesiol. 2007;20:325-330.
41. Ramaesh K, Bhagat S, Wharton SB, et al. Corneal epithelial toxic effects and inflammatory response to perfluorocarbon liquid. Arch Ophthalmol. 1999; 117:1411-1413.
42. Castro CI, Briceno JC. Perfluorocarbon-based oxygen carriers: review of products and trials. Artif Organs. 2010;34:622-634.
43. 2 carriers. Anesthesiol Clin North America. 2005;23:373-389.
44. Riess JG, Krafft MP, eds. Fluorocarbon Emulsions as in vivo Oxygen Delivery Systems: Background and Chemistry. London, England: Academic Press; 2006.
45. Pfannkuch F, Schnoy N. Perfluorochemical-emulsion (fluorocarbon-43) as blood gas carrierVfate of the substance after intravenous injection in rat (author's transl) [in German]. Anaesthesist. 1979;28:511-516.
46. Code RF, Harrison JE, McNeill KG. In vivo measurement of accumulated bone fluorides by nuclear magnetic resonance. J Bone Miner Res. 1990; 5(suppl 1):S91-S94.
47. Klomp D, van Laarhoven H, Scheenen T, et al. Quantitative 19F MR spec-troscopy at 3 T to detect heterogeneous capecitabine metabolism in human liver. NMR Biomed. 2007;20:485-492.
48. Bolo NR, Hode Y, Macher JP. Long-term sequestration of fluorinated compounds in tissues after fluvoxamine or fluoxetine treatment: a fluorine magnetic resonance spectroscopy study in vivo. MAGMA. 2004;16:268-276.
49. Bolo NR, Hode Y, Nedelec JF, et al. Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology. 2000;23:428-438.
50. Schneider E, Bolo NR, Frederick B, et al. Magnetic resonance spectroscopy for measuring the biodistribution and in situ in vivo pharmacokinetics of fluorinated compounds: validation using an investigation of liver and heart disposition of tecastemizole. J Clin Pharm Ther. 2006;31:261-273.
51. Huang Z, Sengar RS, Nigam A, et al. A fluorinated dendrimer-based nano-technology platform: new contrast agents for high field imaging. Invest Radiol. 2010;45:641-654.
52. van Laarhoven HW, Klomp DW, Kamm YJ, et al. In vivo monitoring of capecitabine metabolism in human liver by 19fluorine magnetic resonance spectroscopy at 1.5 and 3 tesla field strength. Cancer Res. 2003;63:7609-7612.
53. Reid DG, Murphy PS. Fluorine magnetic resonance in vivo: a powerful tool in the study of drug distribution and metabolism. Drug Discov Today. 2008;13: 473-480.
54. Klomp DW, Van Laarhoven HW, Kentgens AP, et al. Optimization of localized 19F magnetic resonance spectroscopy for the detection of fluorinated drugs in the human liver. Magn Reson Med. 2003;50:303-308.
55. Bilecen D, Schulte AC, Kaspar A, et al. Detection of the non-steroidal anti-inflammatory drug niflumic acid in humans: a combined 19F-MRS in vivo and in vitro study. NMR in Biomed. 2003;16:144-151.
56. Payne GS, Collins DJ, Loynds P, et al. Quantitative assessment of the hepatic pharmacokinetics of the antimicrobial sitafloxacin in humans using in vivoF magnetic resonance spectroscopy. Br J Clin Pharmacol. 2005;59:244-248.
57. Sassa T, Suhara T, Ikehira H, et al. 19F-magnetic resonance spectroscopy and chemical shift imaging for schizophrenic patients using haloperidol decano-ate. Psychiatry Clin Neurosci. 2002;56:637-642.
58. Strauss WL, Unis AS, Cowan C, et al. Fluorine magnetic resonance spec-troscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders. Am J Psychiatry. 2002; 159:755-760.
59. Henry ME, Moore CM, Kaufman MJ, et al. Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: a fluorine MRS study. Am J Psychiatry. 2000;157:1506-1508.
60. Strauss WL, Dager SR. Magnetization transfer of fluoxetine in the human brain using fluorine magnetic resonance spectroscopy. Biol Psychiatry. 2001; 49:798-802.
61. Miner CM, Davidson JR, Potts NL, et al. Brain fluoxetine measurements using fluorine magnetic resonance spectroscopy in patients with social phobia. Biol Psychiatry. 1995;38:696-698.
62. Komoroski RA, Newton JE, Karson C, et al. Detection of psychoactive drugs in vivo in humans using 19F NMR spectroscopy. Biol Psychiatry. 1991;29: 711-714.
63. Durst P, Schuff N, Crocq MA, et al. Noninvasive in vivo detection of a fluorinated neuroleptic in the human brain by 19F nuclear magnetic resonance spectroscopy. Psychiatry Res. 1990;35:107-114.
64. Procissi D, Claus F, Burgman P, et al. In vivo 19F magnetic resonance spec-troscopy and chemical shift imaging of tri-fluoro-nitroimidazole as a potential hypoxia reporter in solid tumors. Clin Cancer Res. 2007;13:3738-3747.
65. Li CW, Negendank WG, Padavic-Shaller KA, et al. Quantitationof5- fluorouracil catabolism in human liver in vivo by three-dimensional localized 19F magnetic resonance spectroscopy. Clin Cancer Res. 1996;2:339-345.
66. Hideto K, Yoshihiro D, Yoko K. Application of (19)F chemical shift imaging in studies of mice with orally administered 5-fluorouracil. Magn Reson Med. 2001;46:864-869.
67. Kadayakkara DK, Janjic JM, Pusateri LK, et al. In vivo observation of in-tracellular oximetry in perfluorocarbon-labeled glioma cells and chemother-apeutic response in the CNS using fluorine-19 MRI. Magn Reson Med. 2010; 64:1252-1259.
68. Waters EA, Chen J, Yang X, et al. Detection of targeted perfluorocarbon nanoparticle binding using 19F diffusion weighted MR spectroscopy. Magn Reson Med. 2008;60:1232-1236.
69. Winter PM, Neubauer AM, Caruthers SD, et al. Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26:2103-2109.
70. Flogel U, Ding Z, Hardung H, et al. In vivo monitoring of inflammation after cardiac and cerebral ischemia by fluorine magnetic resonance imaging. Circulation. 2008;118:140-148.
71. Neubauer AM, Caruthers SD, Hockett FD, et al. Fluorine cardiovascular magnetic resonance angiography in vivo at 1.5 T with perfluorocarbon nanoparticle contrast agents. J Cardiovasc Magn Reson. 2007;9:565-573.
72. Waters EA, Chen J, Allen JS, et al. Detection and quantification of angio-genesis in experimental valve disease with integrin-targeted nanoparticles and 19-fluorine MRI/MRS. J Cardiovasc Magn Reson. 2008;10:43.
73. de Lange EE, Altes TA, Patrie JT, et al. Changes in regional airflow obstruction over time in the lungs of patients with asthma: evaluation with 3He MR imaging. Radiology. 2009;250:567-575.
74. 129Xe from blood into alveolar gas? Radiology. 2009;252:319-321.
75. Mosbah K, Ruiz-Cabello J, Berthezene Y, et al. Aerosols and gaseous contrast agents for magnetic resonance imaging of the lung. Contrast Media Mol Imaging. 2008;3:173-190.
76. Kuethe DO, Caprihan A, Gach HM, et al. Imaging obstructed ventilation with NMR using inert fluorinated gases. J Appl Physiol. 2000;88:2279-2286.
77. Wolf U, Scholz A, Heussel CP, et al. Subsecond fluorine-19 MRI of the lung. Magn Reson Med. 2006;55:948-951.
78. Adolphi NL, Kuethe DO. Quantitative mapping of ventilation-perfusion ratios in lungs by 19F MR imaging of T1 of inert fluorinated gases. Magn Reson Med. 2008;59:739-746.
79. Scholz AW, Eberle B, Heussel CP, et al. Ventilation-perfusion ratio in per-flubron during partial liquid ventilation. Anesth Analg. 2010;110:1661-1668.
80. Wolf U, Scholz A, Terekhov M, et al. Fluorine-19 MRI of the lung: first human experiment. Proceedings of the 16th Annual International Society for Magnetic Resonance in Medicine, 2008.
81. Miyazaki M, Lee VS. Nonenhanced MR angiography. Radiology. 2008;248: 20-43.
82. van Heeswijk RB, Pilloud Y, Flogel U, et al. Fluorine-19 magnetic resonance angiography of the mouse. PLoS One. 2012;7:e42236.
83. Riess JG. Overview of progress in the fluorocarbon approach to in vivo oxygen delivery. Biomater Artif Cells Immobilization Biotechnol. 1992;20: 183-202.
84. Kocian R, Spahn DR. Haemoglobin, oxygen carriers and perioperative organ perfusion. Best Pract Res Clin Anaesthesiol. 2008;22:63-80.
85. Spahn DR, Leone BJ, Reves JG, et al. Cardiovascular and coronary physiology of acute isovolemic hemodilution: a review of nonoxygen-carrying and oxygen-carrying solutions. Anesth Analg. 1994;78:1000-1021.
86. Spahn DR. Blood substitutes. Artificial oxygen carriers: perfluorocarbon emulsions. Crit Care. 1999;3:R93-R97.
87. Kataoka K, Kwon GS, Yokoyama M, et al. Block copolymer micelles as vehicles for drug delivery. J Control Release. 1993;24:119-132.
88. Keipert PE. Use of Oxygent, a perfluorochemical-based oxygen carrier, as an alternative to intraoperative blood transfusion. Artif Cells Blood Substit Immobil Biotechnol. 1995;23:381-394.
89. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 2003;17:545-580.
90. Margolis DJ, Hoffman JM, Herfkens RJ, et al. Molecular imaging techniques in body imaging. Radiology. 2007;245:333-356.
91. Rudin M, Rausch M, Stoeckli M. Molecular imaging in drug discovery and development: potential and limitations of nonnuclear methods. Mol Imaging Biol. 2005;7:5-13.
92. Jaffer FA, Weissleder R. Molecular imaging in the clinical arena. JAMA. 2005;293:855-862.
93. Mulder WJ, Strijkers GJ, van Tilborg GA, et al. Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging. NMR Biomed. 2006;19: 142-164.
94. Sipkins DA, Cheresh DA, Kazemi MR, et al. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med. 1998;4:623-626.
95. Weissleder R. Molecular imaging in cancer. Science. 2006;312:1168-1171.
96. Oostendorp M, Post MJ, Backes WH. Vessel growth and function: depiction with contrast-enhanced MR imaging. Radiology. 2009;251:317-335.
97. Winter PM, Caruthers SD, Yu X, et al. Improved molecular imaging contrast agent for detection of human thrombus. Magn Reson Med. 2003;50:411-416.
98. Flacke S, Fischer S, Scott MJ, et al. Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation. 2001;104:1280-1285.
99. Cyrus T, Lanza GM, Wickline SA. Molecular imaging by cardiovascular MR. J Cardiovasc Magn Reson. 2007;9:827-843.
100. Caruthers SD. In vitro demonstration using 19F MR to augment molecular imaging with paramagnetic perfluorocarbon nanoparticles at 1.5 tesla. Invest Radiol. 2006;41:305-312.
101. Partlow KC, Chen J, Brant JA, et al. 19F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nano-beacons. FASEB J. 2007;21:1647-1654.
102. Keupp J, Rahmer J, Grasslin I, et al. Simultaneous dual-nuclei imaging for motion corrected detection and quantification of 19F imaging agents. Magn Reson Med. 2011;66:1116-1122.
103. Wolters M, Oostendorp M, Coolen BF, et al. Efficacy of positive contrast imaging techniques for molecular MRI of tumor angiogenesis. Contrast Media Mol Imaging. 2012;7:130-139.
104. Skobe M, Rockwell P, Goldstein N, et al. Halting angiogenesis suppresses carcinoma cell invasion. Nat Med. 1997;3:1222-1227.
105. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature. 2001;410:701-705.
106. Genovese J, Cortes-Morichetti M, Chachques E, et al. Cell based approaches for myocardial regeneration and artificial myocardium. Curr Stem Cell Res Ther. 2007;2:121-127.
107. Pera MF, Tam PP. Extrinsic regulation of pluripotent stem cells. Nature. 2010; 465:713-720.
108. Martino G, Franklin RJ, Baron Van Evercooren A, et al. Stem cell transplantation in multiple sclerosis: current status and future prospects. Nat Rev Neurol. 2010;6:247-255.
109. Kerkar SP, Restifo NP. Cellular constituents of immune escape within the tumor microenvironment. Cancer Res. 2012;72:3125-3130.
110. Srinivas M, Aarntzen EH, Bulte JW, et al. Imaging of cellular therapies. Adv Drug Deliv Rev. 2010;62:1080-1093.
111. Ahrens ET, Flores R, Xu H, et al. In vivo imaging platform for tracking im-munotherapeutic cells. Nat Biotechnol. 2005;23:983-987.
112. Ebner B, Behm P, Jacoby C, et al. Early assessment of pulmonary inflammation by 19F MRI in vivo. Circ Cardiovasc Imaging. 2010;3:202-210.
113. Flogel U, Su S, Kreideweiss I, et al. Noninvasive detection of graft rejection by in vivo (19) F MRI in the early stage. Am J Transplant. 2011;11:235-244.
114. Weise G, Basse-Lusebrink TC, Kleinschnitz C, et al. In vivo imaging of stepwise vessel occlusion in cerebral photothrombosis of mice by 19F MRI. PLoS One. 2011;6:e28143.
115. Trott CM, El Fakhri G. Sequential and simultaneous dual-isotope brain SPECT: comparison with PET for estimation and discrimination tasks in early Parkinson disease. Med Phys. 2008;35:3343-3353.
116. Hsieh PC, Lee IH, Yeh TL, et al. Distribution volume ratio of serotonin and dopamine transporters in euthymic patients with a history of major depressionVa dual-isotope SPECT study. Psychiatry Res. 2010;184:157-161.
117. Hachamovitch R, Kang X, Amanullah AM, et al. Prognostic implications of myocardial perfusion single-photon emission computed tomography in the elderly. Circulation. 2009;120:2197-2206.
118. Miserus RJ, Herias MV, Prinzen L, et al. Molecular MRI of early thrombus formation using a bimodal alpha2-antiplasmin-based contrast agent. JACC Cardiovasc Imaging. 2009;2:987-996.
119. Mistretta CA. Undersampled radial MR acquisition and highly constrained back projection (HYPR) reconstruction: potential medical imaging applications in the post-Nyquist era. J Magn Reson Imaging. 2009;29:501-516.
120. 19F CSI. J Magn Reson. 2010;207:262-273.
121. Keupp J, Schmieder AH, Williams TA, et al. Ultra-short echo time 19F/1H imaging of gadolinium-free perfluoro-carbon nanoparticles: a robust method for in vivo angiogenesis imaging. Proceedings of the 19th Annual International Society for Magnetic Resonance in Medicine, 2011.
122. Du J, Hamilton G, Takahashi A, et al. Ultrashort echo time spectroscopic imaging (UTESI) of cortical bone. Magn Reson Med. 2007;58:1001-1009.